Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550
mg three times a day in patients with IBS with diarrhea who respond to initial treatment of
rifaximin 550 mg three times a day.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.